should be more amenable to crystallization. How does PI3K activation assist in the pheromone response? Slessareva et al. (2006) show that it may help Gβγ to activate MAP kinase, but possible mechanisms for this are hard to fathom given our current knowledge. Finally, the authors propose that Gα might cycle between GDP and GTP bound forms at the endosome, and this would require a nucleotide exchange factor at the endosome to catalyze the cycle. Could this exchange factor simply be an endocytosed pheromone receptor acting in the same manner as it does at the plasma membrane, or is some new exchange factor required? Despite these unresolved issues, Slessareva et al. (2006) make a major contribution to our understanding of heterotrimeric G protein signaling by identifying an intracellular G protein effector and establishing its physiological significance in signaling through rigorous genetic tests.
Is yeast pheromone signaling relevant to signaling in humans? Anyone who doubts this should look to history. Studies of yeast pheromone signaling first established that Gβγ could activate downstream signaling events. The first member of the RGS class of Gα GTPase activators was also identified through studies of pheromone signaling. In both cases, it was years before it was appreciated that signaling in vertebrates works the same way. The identification of PI3K as an intracellular G protein effector is the first major addition to the yeast pheromone signaling pathway in over 10 years. There is already a hint that heterotrimeric G proteins regulate lipid kinases at intracellular membranes in mammalian cells (Jamora et al., 1999) , and we look forward to follow-up studies.
Structurally speaking, the convoluted folds (cristae) of the mitochondrial inner membrane were once viewed simply as a barrier that separated the mitochondria into the inner matrix and the intermembrane space (IMS). The pioneering studies of mitochondrial structure by Mannella, Frey, and coworkers using electron tomography changed this view. They showed that the lamellar and tubular structure of the mitochondrial inner membrane generates a third type of compartment, created by juxtaposition of innermembrane folds. These intra-cristae regions form a barrier to diffusion of proteins (Frey and Mannella, 2000) . This shifting view of mitochondrial structure has important implications for our understanding of apoptosis.
Several apoptogenic proteins, in particular cytochrome c, reside in the mitochondrial IMS. Predictions based on studies using electron tomography suggest that most cytochrome c is "trapped" in the intra-cristae regions, with limited access to the IMS (Figure 1 A change in the shape of mitochondrial cristae must take place to attain rapid and complete release of cytochrome c during apoptosis. In this issue of Cell, Cipolat et al. (2006) and Frezza et al. (2006) show that a rhomboid intramembrane protease PARL and a dynaminrelated protein OPA1 are critical regulators of cristae remodeling.
the cristae configuration, eliminating the diffusion barrier and freeing cytochrome c from the cristae to the IMS. The second step is the release of cytochrome c into the cytosol via pores in the mitochondrial outer membrane (Figure 1 ) (Scorrano et al., 2002) . Although the final release of cytochrome c through the mitochondrial outer membrane requires the proapoptotic Bcl-2 family proteins Bak and Bax, cristae remodeling does not. Two reports in this issue of Cell show that cristae remodeling during apoptosis, which leads to the release of cytochrome c, is regulated by a rhomboid protease PARL and a dynamin-related protein OPA1 Frezza et al., 2006) .
Cristae remodeling was not the first link established between mitochondrial structure and apoptosis. As their Greek name implies, mito-(thread) chondria (grains) are pleiomorphic organelles. They form either short rod-like structures or continuous filamentous structures (or "spaghetti and meatballs" as coined by Paolo Bernardi and John Lemasters). These structures are shaped by opposing mechanisms: mitochondrial fusion and mitochondrial fission (Youle and Karbowski, 2005) . Mitochondrial fusion and fission in yeast and mammals are very similar and the players known thus far are conserved between the species. These include the extended dynamin family of proteins (Danino and Hinshaw, 2001) : mitofusin (MFN) 1 and 2 (Fzo1 in yeast) and OPA1 (Mgm1) required for mitochondrial fusion and DRP1 (Dnm1) required for mitochondrial fission (for a detailed list see Youle and Karbowski, 2005) .
Youle and coworkers characterized the first link between mitochondrial fission and apoptosis, showing that DRP1 is essential for cytochrome c release (Frank et al., 2001) . Subsequent studies described the proand antiapoptotic roles of proteins involved in mitochondrial fission or fusion, respectively (Youle and Karbowski, 2005) . However, the mechanism by which mitochondrial fission may contribute to cytochrome c release has remained elusive. It was then shown that DRP1 induces cristae remodeling in addition to its role in mitochondrial fission (Germain et al., 2005) , but whether this second function of DRP1 requires mitochondrial fission is unclear.
The two new reports in this issue provide insights into the mechanism of cristae remodeling during apoptosis . Surprisingly, the stars of this performance are PARL (Rbd1 in yeast) and OPA1 (Mgm1), which are known to regulate mitochondrial fusion in yeast (McQuibban et al., 2003) . Both reports indicate that the antiapoptotic effects of these proteins are independent of mitochondrial fusion, yet there are functional similarities between the mammalian and the corresponding yeast proteins. Both PARL and Rbd1 are rhomboid proteases, which are intramembrane serine proteases, and both are localized to the mitochondrial inner membrane. The new reports suggest (though they do not directly show) that as in yeast, where Mgm1 is a substrate of Rbd1 (McQuibban et al., 2003) , mitochondrial PARL cleaves the OPA1 protein.
The cleavage of OPA1 generates a pool of truncated OPA1 that is soluble in the IMS. This soluble OPA1 is crucial for the antiapoptotic effects of PARL because it maintains the bottleneck configuration of cristae and the compartmentalization of cytochrome c (Figure 1) .
The study by Cipolat et al. (2006) reveals that mice lacking PARL die shortly after 8 weeks of age with progressive cachexia manifested mostly by muscle loss. The spleen and thymus of PARL-deficient mice were also severely atrophic. Considering that Rbd1-deficient yeast cannot grow on nonfermentable medium (McQuibban et al., 2003) and that myopathy is a common feature of mitochondrial disorders, it was reasonable to assume that PARL-deficient mice have a severe defect in oxidative phosphorylation. However, studies of mitochondria isolated from tissues of PARL-deficient mice could not reveal such a defect. On the other hand, extensive apopto- Prior to the permeabilization of the mitochondrial outer membrane, matrix remodeling is required for a swift and complete release of cytochrome c. OPA1 comes in two sizes: the larger form is embedded in the mitochondrial inner membrane (IM) and the smaller soluble form is found in the intermembrane space (IMS) and plays a critical role in maintaining the bottleneck structure of the cristae. PARL, an intramembrane protease, regulates OPA1 processing. During apoptosis, the OPA1 hetero-oligomer is disrupted, leading to unraveling of the cristae and cytochrome c diffusion to the IMS. Following perforation of the mitochondrial outer membrane (usually due to Bak/Bax activity), cytochrome c is released to the cytosol where it forms the apoptosome (oligomers of Apaf-1, cytochrome c, and pro-caspase-9) and leads to further downstream events that trigger full-blown apoptosis. sis was detected in lymphocytes, explaining the loss of mass in the spleen and thymus. Cipolat et al. therefore suggested that apoptosis may explain muscle fiber loss and went on to characterize the role of PARL in apoptosis. Using mouse embryonic fibroblasts (MEFs), they confirmed that PARL protects cells from the intrinsic, mitochondriadependent, apoptotic pathway but not from extrinsic stimuli, such as treatment with TNFα. Because Rbd1 cleaves Mgm1 in yeast, and because OPA1, its mammalian homolog, is known to have antiapoptotic activity, the authors investigated the role of OPA1 in PARL's antiapoptotic activity. Interestingly, overexpression of OPA1 had antiapoptotic effects in wild-type MEFs but not those lacking PARL. In contrast, reducing expression of OPA1 in PARL-deficient cells using short hairpin RNAs (shRNAs) circumvented the antiapoptotic effect of PARL added exogenously. This indicated that neither of these proteins has antiapoptotic activity independent of the other. Borrowing from the yeast system, Cipolat et al. investigated whether PARL cleaves OPA1, generating a short form that is antiapoptotic. Indeed, they observed that these proteins interact on the mitochondrial inner membrane. They also found a short form of OPA1 in the IMS region of mitochondria from wild-type cells. This short form of OPA1 was less abundant in the IMS of PARL-deficient cells. Importantly, the overexpression of an IMS-targeted short OPA1 had antiapoptotic activity in both wild-type cells and in cells lacking PARL. These results are consistent with the claim that OPA1 cleavage is PARL dependent and that a shorter form of OPA1, which is found in the IMS, mediates the antiapoptotic activity of PARL.
The work by Frezza et al. (2006) provides additional information on OPA1 and cristae remodeling. This study investigated the mechanisms of availability of cytochrome c to the IMS. Frezza et al. treated isolated mitochondria with the cleaved active form of the proapoptotic Bcl-2 family member Bid (cBid), showing that cytochrome c release from the mitochondria of cells overexpressing OPA1 was markedly slower than for wild-type cells. This finding was independent of mitochondrial fusion because OPA1 had the same effect in cells deficient in MFN1 and MFN2, which are required for mitochondrial fusion. Furthermore, in mitochondria isolated from cells in which OPA1 expression was reduced by shRNAs or inhibited by a dominant-negative mutant, cytochrome c release was much faster. To show that OPA1 controls cytochrome c release by regulating its accessibility to the IMS, the mitochondria were briefly incubated with cBid, and cytochrome c mobilization was examined using either outer membrane permeabilization with a mild detergent or respiratory assays. In respiratory assays, ascorbate or NADH were used as electron donors capable of reducing cytochrome c (directly or indirectly) only when it is free in the IMS. Extensive studies using electron microscopy and electron tomography confirmed that OPA1 maintained the bottleneck structure of the cristae-IMS junction in mitochondria treated with cBid.
These investigators propose a mechanism for how the IMS-soluble OPA1 that is induced by PARL maintains cristae structure. They showed that the short and long forms of OPA1 form hetero-oligomers that are disrupted soon after cBid treatment, when cristae remodeling is observed and cytochrome c is still retained in the IMS. They propose a provocative model in which OPA1 clamps the mitochondrial inner membrane by linking the long, membrane bound forms with the shorter IMS ones (Figure 1) . Indeed, under hypotonic conditions, when the inner membrane swells, OPA1 did not form oligomers, indicating that the disruption of cristae structure dissociates OPA1 heteromers.
The two new studies suggest that the PARL-OPA1 duo is required for maintaining the tightly folded structure of the mitochondrial inner membrane. Given that both full-length and truncated OPA1 are needed, OPA1 must first be truncated by PARL to achieve a fully functional cristaetightening complex. Whether OPA1 is the only component in this complex has yet to be determined. Unlike the case in yeast, OPA1 truncation by PARL may not be required for mitochondrial fusion because loss of PARL does not affect the fusion process. This may be explained by the fact that small amounts of truncated OPA1 are observed in PARL-deficient cells or that truncated OPA1 is not required for mitochondrial fusion. The fact that the antiapoptotic activity of OPA1 is independent of its profusion activity does not rule out the need for mitochondrial fission during apoptosis. The connection between mitochondrial fission and cristae remodeling needs further investigation. In particular, the role of DRP1 in regulating cristae structure needs to be clarified. Moreover, what leads to the dissociation of the OPA1 oligomer early after cBid treatment (and other apoptogenic signals) is still an open question.
